Merck temporarily suspends enrollment in vaccine trial

Intercell AG, and its partner Merck & Co, have announced that they are temporarily suspending enrollment in a Phase 2/3 trial of a vaccine for the prevention of Staphylococcus aureus infection on the advice of the data monitoring committee.